Fidelity Investments’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Fidelity Investments’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30	Closed	-$18	–	5770
2024 Q4	$18	Buy	+30	New	+$21	﹤0.01%	5390
2023 Q2	–	Sell	-300	Closed	-$252	–	5628
2023 Q1	$252	Buy	+300	New	+$427	﹤0.01%	4839

Fidelity Investments's CYTH Position: Q1 2025 in Review

Fidelity Investments sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 30 shares — an estimated $18 sold.

Fidelity Investments first reported a position in CYTH in Q1 2023 and held it in 2 quarters. The position peaked at $252 in Q1 2023. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.

Fidelity Investments reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Fidelity Investments sold 30 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $18.
Fidelity Investments first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
Fidelity Investments's Cyclo Therapeutics, Inc. Common Stock position peaked at $252 in Q1 2023.
0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Fidelity Investments's 13F filing for Q1 2025, filed 12 May 2025.